Cellectar Biosciences, Inc.
16
1
4
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
4 terminated/withdrawn out of 16 trials
66.7%
-19.8% vs industry average
6%
1 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Role: lead
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Role: lead
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Role: lead
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Role: lead
CLR 131 Combined With Radiation for Head and Neck Cancer
Role: collaborator
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Role: lead
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Role: lead
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
Role: lead
Study of 124I-NM404 in Advanced Solid Malignancies
Role: collaborator
NM404 as an Imaging Agent in Patients With NSCLC
Role: collaborator
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Role: lead
Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
Role: lead
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
Role: lead
Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
Role: lead
NOV-002 in Myelodysplastic Syndrome (MDS)
Role: collaborator
Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy
Role: lead
All 16 trials loaded